BioFire Defense, LLC, announced on March 18 that it received a Next Generation Diagnostic System Technology Development contract from the U.S. Department of Defense.
The contract is an 8-year, $240 million agreement for BioFire to work on the NGDS, which will expand the company's diagnostics by developing biothreat test capabilities for use in the DoD.
"This is a fantastic opportunity to deliver the most cutting edge diagnostic system to our Warfighter," BioFire Defense CEO Kirk Ririe said. "The motivated team at (Joint Program Executive Office) has pushed an aggressive schedule and a cost effective approach that will be met by exploiting our FilmArray's commercial diagnostic capabilities, to provide for our Nation's biodefense and improve DoD health care."
The new standard of biowarfare detection will be developed by the GNDS program, and will replace the DoD's current Joint Biologic Agent Identification and Diagnostic System. The FilmArray platform will enable the DoD to detect bioterror pathogens in addition to running a full suite of diagnostic tests, including respiratory and blood cultures.
Included in the contract is an option to develop additional test panels and improvements to increase the durability of the platform.
BioFire Defense is a subsidiary of bioMerieux, Inc. The company is focused on technology innovations, pathogen identification and life sciences.